Truist initiated coverage of Vanda Pharmaceuticals (VNDA) with a Buy rating and $18 price target With three commercial drugs commanding $200M in sales plus “a slew of higher value near-commercial-ready assets nearing launch,” the firm sees Vanda’s reformulation of lead asset Fanapt launching with improved economics into a competitive schizophrenia and bipolar market differentiated by lower weight gain risk. “More interestingly” is Vanda’s first-mover advantage of Nereus into adjunct therapy for GLP-1 induced vomiting, as the firm sees this as a derisked $1B opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- AnaptysBio provides update on potential spin-off of biopharma operations
- Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz
- Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price
- Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
- Vanda announces FDA accepted BLA for imsidolimab